Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Endocrinology
•
Thyroid Disorders
Would you increase or maintain the same initial dose of methimazole for treatment of hyperthyroidism if symptoms and thyroid tests improve but are not normalized?
Related Questions
How often should TSH levels be monitored in patients with a history of Graves' disease who are in remission with negative TSI/TBII antibodies and off medical therapy?
Do SSRIs affect the absorption of Levothyroxine therapy when taken concomitantly?
For hypothyroid patients on dual replacement therapy (levothyroxine & liothyronine), do you recommend monitoring TSH while holding off on the morning T3 dose?
What work up do you recommend for persistent subclinical hyperthyroidism with decreased RAI uptake and negative thyroid antibody tests?
What is the clinical significance of positive anti-thyroid antibodies in a patient that is post-thyroidectomy?
What specific features in a patient with euthyroid MNG increase their risk of developing functional autonomy and overt hyperthyroidism?
Which brand/preparation of levothyroxine do you recommend to treat hypothyroid patients with alpha-gal allergy?
Would you recommend changing a patient from the pill form of levothyroxine to Tirosint-SOL if they are started on a proton pump inhibitor?
In patients with differentiated thyroid cancer, do you consider pathology characteristics not found in the ATA risk stratification guidelines (ie microscopic margins or multifocal cancer) when determining recurrence risk and management?
How does papillary thyroid carcinoma with tall cell features (PTC TCF) compare to tall cell variant papillary thyroid carcinoma (TCV PTC) with regards to their clinicohistopathological features and risk of recurrence?
